文献速递乳腺癌头颈与中枢神经肿瘤

乳腺癌脑转移中的内在亚型转换及获得性ERBB2/HER2扩增与突变

Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases.
PubMed 文献 · JAMA Oncol · 2017-01-01

该研究对比20例原发乳腺癌与配对脑转移灶,发现17例脑转移灶保留原发PAM50亚型,但17例存在可靶向基因表达改变,其中7例ERBB2/HER2表达增益超过2倍,3例原阴性转为免疫组化阳性;独立数据集中9例ERBB2/HER2阴性病例有2例脑转移转为阳性。

要点

  • 20例配对原发与脑转移灶中,17例脑转移灶保留原发PAM50亚型。
  • 7/20例脑转移灶ERBB2/HER2表达增益超过2倍,其中3例原阴性转为免疫组化3+。
  • 独立数据集中9例ERBB2/HER2阴性病例有2例脑转移转为阳性,1例为扩增、1例为V777L突变。

核心结论

  • 乳腺癌脑转移常获得可靶向基因改变,约20%的ERBB2/HER2阴性病例在转移灶获得ERBB2/HER2改变。
  • 这些观察对ERBB2/HER2阴性乳腺癌患者有直接临床意义,并支持对转移灶进行全面分子分析以指导临床诊疗。

研究设计与样本

  • 纳入来自2家学术机构的20例原发乳腺癌组织及切除脑转移灶(10例雌激素受体阴性、10例雌激素受体阳性)。
  • 发现队列的合格病例需有患者配对的原始乳腺癌组织及切除脑转移灶,由于配对样本罕见未设排除标准。
  • 使用两个验证测序队列:一个已发表的17例患者配对脑转移数据集,以及一个富集转移样本的7884例乳腺癌肿瘤队列。

主要发现

  • 20例脑转移灶中17例保留原发乳腺癌的PAM50亚型。
  • 20例脑转移灶中17例存在可靶向基因的表达改变(小于2倍或大于2倍),包括FGFR4增益6例(30%)、FLT1增益4例(20%)、AURKA增益2例(10%)和ESR1表达缺失9例(45%)。
  • 最常见的复发性表达增益为ERBB2/HER2,20例脑转移灶中7例(35%)表达增加超过2倍。
  • 这7例中3例在原发乳腺癌队列13例ERBB2/HER2阴性中为阴性,在配对脑转移灶中变为免疫组化阳性(3+),并伴有转移灶特异性ERBB2/HER2位点扩增。
  • 独立数据集中9例ERBB2/HER2阴性乳腺癌有2例(22.2%)转为ERBB2/HER2阳性,其中1例脑转移灶获得ERBB2/HER2扩增,另1例显示转移灶富集激活性V777L ERBB2/HER2突变。

临床怎么用

  • 作者认为这些观察对ERBB2/HER2阴性乳腺癌患者有直接临床意义,并支持对转移灶进行全面分子分析以指导临床诊疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with breast cancer (BrCa) brain metastases (BrM) have limited therapeutic options. A better understanding of molecular alterations acquired in BrM could identify clinically actionable metastatic dependencies. OBJECTIVE: To determine whether there are intrinsic subtype differences between primary tumors and matched BrM and to uncover BrM-acquired alterations that are clinically actionable. DESIGN, SETTING, AND PARTICIPANTS: In total, 20 cases of primary breast cancer tissue and resected BrM (10 estrogen receptor [ER]-negative and 10 ER-positive) from 2 academic institutions were included. Eligible cases in the discovery cohort harbored patient-matched primary breast cancer tissue and resected BrM. Given the rarity of patient-matched samples, no exclusion criteria were enacted. Two validation sequencing cohorts were used-a published data set of 17 patient-matched cases of BrM and a cohort of 7884 BrCa tumors enriched for metastatic samples. MAIN OUTCOMES AND MEASURES: Brain metastases expression changes in 127 genes within BrCa signatures, PAM50 assignments, and ERBB2/HER2 DNA-level gains. RESULTS: Overall, 17 of 20 BrM retained the PAM50 subtype of the primary BrCa. Despite this concordance, 17 of 20 BrM harbored expression changes (<2-fold or >2-fold) in clinically actionable genes including gains of FGFR4 (n = 6 [30%]), FLT1 (n = 4 [20%]), AURKA (n = 2 [10%]) and loss of ESR1 expression (n = 9 [45%]). The most recurrent expression gain was ERBB2/HER2, which showed a greater than 2-fold expression increase in 7 of 20 BrM (35%). Three of these 7 cases were ERBB2/HER2-negative out of 13 ERBB2/HER2-negative in the primary BrCa cohort and became immunohistochemical positive (3+) in the paired BrM with metastasis-specific amplification of the ERBB2/HER2 locus. In an independent data set, 2 of 9 (22.2%) ERBB2/HER2-negative BrCa switched to ERBB2/HER2-positive with 1 BrM acquiring ERBB2/HER2 amplification and the other showing metastatic enrichment of the activating V777L ERBB2/HER2 mutation. An expanded cohort revealed that ERBB2/HER2 amplification and/or mutation frequency was unchanged between local disease and metastases across all sites; however, a significant enrichment was appreciated for BrM (13% local vs 24% BrM; P < .001). CONCLUSIONS AND RELEVANCE: Breast cancer BrM commonly acquire alterations in clinically actionable genes, with metastasis-acquired ERBB2/HER2 alterations in approximately 20% of ERBB2/HER2-negative cases. These observations have immediate clinical implications for patients with ERBB2/HER2-negative breast cancer and support comprehensive profiling of metastases to inform clinical care.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Priedigkeit N, Hartmaier RJ, Chen Y, et al. Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases. JAMA Oncol. 2017. PMID: 27926948. doi:10.1001/jamaoncol.2016.5630

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。